Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors

Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study.